Meluha Therapeutics

Meluha Therapeutics is a clinical-stage biopharmaceutical company based in Malaysia that specializes in developing and manufacturing novel stem cell and exosome-based therapies. The company's lead product, Chondrogen, is an investigational treatment combining allogeneic human Wharton's Jelly-derived mesenchymal stem cells (hWJ-MSCs) with a hyaluronic acid scaffold, designed for intra-articular injection to treat knee cartilage defects and osteoarthritis. Meluha also develops myCell, another advanced regenerative cell therapy derived from hWJ-MSCs, and is exploring exosome-based treatments for conditions like Type 2 diabetes. Acquired by Synergy Empire Limited in March 2025, Meluha operates a state-of-the-art cGMP manufacturing facility to supply hospitals and clinics across Malaysia and Southeast Asia.